The Truman Genome: How IVF andGenomics Built a Nearly $1 BillionIndustry Nobody Talks About
What is preimplantation genetic testing and why is it one of the fastest-growing genomics markets most people have never heard of? Preimplantation genetic testing (PGT) is a suite of genomic screening techniques used during IVF to assess embryos for chromosomal abnormalities and hereditary diseases before implantation. It is quietly becoming one of the most commercially significant applications of genomics in everyday life.
Before the embryo is transferred. Before the pregnancy begins. Before any decision is made that cannot be unmade.
That is when preimplantation genetic testing happens - in the window between a fertilized egg in a laboratory dish and a potential human life. Genomic sequencing reads the chromosomes of
an embryo, identifies abnormalities, and informs which embryo offers the best chance of a healthy pregnancy.
Most people going through IVF know this technology exists. Few appreciate what it has become commercially, or where it is going.
The global PGT market was valued at approximately $598 million in 2026, according to Persistence Market Research, and is projected to reach $1.08 billion by 2033 at an 8.8 percent annual growth rate. This is a genomics business hiding in plain sight inside fertility medicine.
What PGT Actually Does
PGT encompasses three procedures. PGT-A screens embryos for aneuploidy - an abnormal chromosome count, the leading cause of IVF failure and miscarriage, which becomes more common as maternal age rises. PGT-M tests for specific monogenic diseases - single-gene disorders like cystic fibrosis, sickle cell disease, or BRCA-related cancer risk. PGT-SR identifies structural chromosomal rearrangements that cause implantation failure or birth defects.
The underlying technology has evolved rapidly. Early PGT used fluorescence in-situ hybridization, which could analyze only a handful of chromosomes. Next-generation sequencing now allows simultaneous screening for chromosomal abnormalities, single-gene disorders, and structural rearrangements from a single embryo biopsy. Non-invasive PGT-A, which analyzes DNA shed into the culture medium surrounding the embryo rather than biopsying the embryo itself, is now commercially available and represents the next frontier.
The Commercial Landscape
The companies winning in this market are not primarily thought of as genomics companies.
Illumina (ILMN:NASDAQ) supplies the sequencing platforms underpinning most PGT laboratory workflows globally. Thermo Fisher Scientific (TMO:NYSE) offers NGS-based PGT kits for its fully automated Ion Torrent sequencer. CooperSurgical, a subsidiary of The Cooper Companies (COO:NYSE), runs the PGTai platform - applying machine learning to embryo biopsy data to improve interpretation of PGT-A results. Igenomix, acquired by Vitrolife (VITR:Nasdaq
Stockholm) in 2021, offers AI-integrated chromosomal analysis and embryo assessment. Natera (NTRA:NASDAQ) has expanded into non-invasive embryo screening solutions from its prenatal testing base.
The Designer Baby Question
For most of its history, PGT was positioned as a medical tool: a way to avoid implanting embryos with serious chromosomal errors or severe hereditary diseases. That framing enjoyed broad acceptance.
Polygenic screening changes the nature of that choice. A polygenic score aggregates the effect of thousands of small genetic variants to estimate the probability of a complex trait - not just a single-gene disease, but risk for heart disease, diabetes, or schizophrenia. Companies are now beginning to offer polygenic scoring on embryos as an add-on to standard PGT, allowing prospective parents to select among genetically normal embryos based on estimated disease risk across multiple conditions simultaneously.
The ethical debate is not new. The commercial infrastructure to execute it at scale now is.
According to the American Society for Reproductive Medicine, approximately 1 in 6 adults globally experience infertility. More than 250,000 IVF cycles are performed annually in the United States alone, each costing $12,000 to $15,000 with PGT. North America leads with approximately 40 percent of global market share. Asia-Pacific is the fastest-growing region at nearly 11 percent CAGR.
Nobody called it a genomics business. It became one anyway.